Skip navigation

Catalog

Instructor led
Added:07/08/2022 4:30 PM

July 28, 2022 | 6:00 - 7:00 PM Eastern Time
CME Information: 1.0 AMA PRA Category 1 CreditsTM
Speaker: Sherif Nagueh, MD, FASE
Join Dr. Nagueh as he shows how multimodality imaging plays a crucial role in the initial evaluation of patients with known or suspected HCM.
Learning Objectives:
Learn how to use multimodality imaging for patients with increased LV wall thickness
Demonstrate the assessment of dynamic obstruction, including provocable gradients, and mitral valve anatomy
Implement multimodality imaging for risk stratification and prognostication
Use multimodality imaging for the assessment of ischemia and coronary artery disease
Credits awarded per Session. See individual Sessions for further details.
Credits awarded
Type
Name
Sub type
Value
Certificate awarded

About this item

July 28, 2022 | 6:00 - 7:00 PM Eastern Time

CME Information: 1.0 AMA PRA Category 1 CreditsTM 

Speaker:  Sherif Nagueh, MD, FASE

Join Dr. Nagueh as he shows how multimodality imaging plays a crucial role in the initial evaluation of patients with known or suspected HCM. 

Learning Objectives: 

  • Learn how to use multimodality imaging for patients with increased LV wall thickness
  • Demonstrate the assessment of dynamic obstruction, including provocable gradients, and mitral valve anatomy
  • Implement multimodality imaging for risk stratification and prognostication
  • Use multimodality imaging for the assessment of ischemia and coronary artery disease

 

Course/Activity Information

Join Dr. Nagueh as he shows how multimodality imaging plays a crucial role in the initial evaluation of patients with known or suspected HCM. 

In conjunction with clinical findings, imaging can confirm or refute the diagnosis. Imaging should be performed at clinical sites/centers of excellence with experience in the diagnosis and management of HCM. Imaging is central to risk stratification for sudden cardiac death as well as the evaluation of patients with chest pain and possible CAD. Along with ECG, imaging with echocardiography and/or CMR is needed for screening. In addition, imaging can guide treatment for obstructive HCM, be it with negative inotropic drugs, septal reduction therapy, or TEER of the mitral valve. The imaging staff should have a clear understanding of the strengths and limitations of the different imaging modalities and the clinical implications of the findings ascertained by imaging. Importantly, the results should be communicated clearly with the clinical team taking care of the patient. 

Since the publication of the recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy (HCM) in 2011, an impressive growth and evolution of imaging techniques has occurred, enhancing both the recognition and management of the disease. Thus an update was needed to provide recommendations that take into account these recent developments.

Other information

  • Training Hours: 1.00
  • Additional Charges May Apply

    Ratings and reviews